EA
VNDA icon

Emerald Acquisition’s Vanda Pharmaceuticals VNDA Stock Holding History

Emerald Acquisition’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$1.56M Buy
93,806
+44,384
+90% +$598K ﹤0.01% 1879
2016
Q2 		$553K Buy
+49,422
New +$479K ﹤0.01% 2428

Other funds holding VNDA

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Emerald Acquisition's VNDA Position: Q3 2016 in Review

Emerald Acquisition increased its Vanda Pharmaceuticals (VNDA) stake by 90% in Q3 2016, buying an estimated $598K and bringing the position to 93,806 shares worth $1.56M. The position accounts for ﹤0.01% of the portfolio, ranked #1879.

Emerald Acquisition first reported a position in VNDA in Q2 2016 and has held it in 2 quarters since. 140 funds tracked by Wall St. Rank hold VNDA as of Q3 2016.

  • Emerald Acquisition held 93,806 shares of Vanda Pharmaceuticals worth $1.56M as of Q3 2016.
  • Emerald Acquisition bought 44,384 Vanda Pharmaceuticals shares in Q3 2016, an estimated $598K.
  • Vanda Pharmaceuticals made up ﹤0.01% of Emerald Acquisition's portfolio in Q3 2016, its #1879 holding.
  • Emerald Acquisition first reported a position in Vanda Pharmaceuticals in Q2 2016 and has held it in 2 quarters since.
  • 140 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2016.

Based on Emerald Acquisition's 13F filing for Q3 2016, filed 9 Nov 2016.